NAD Supplement Guide: NMN, NR, NADH and Oral NAD+ Precursors Compared

At a Glance

Declining NAD+ is one of the most reproducible biomarkers of biological aging. By mid-life, tissue NAD+ concentrations are roughly half what they were at 20 — and the gap between “normal” aging and accelerated aging often shows up first in mitochondrial efficiency and DNA repair capacity. Choosing the right oral precursor, at the right dose, with the right cofactors, is where most patients get lost. This guide walks through each option with the clinical hierarchy of evidence behind it.

Why NAD+ Declines and Why It Matters

NAD+ (nicotinamide adenine dinucleotide) is not a single molecule serving a single pathway. It is a coenzyme that cycles between oxidised (NAD+) and reduced (NADH) forms across hundreds of enzymatic reactions — electron transport, glycolysis, the TCA cycle, PARP-mediated DNA repair, and sirtuin deacetylase signalling among them.

Three mechanisms drive the age-related decline:

1. CD38 upregulation. This enzyme degrades NAD+ and is activated by chronic, low-grade inflammation — the same “inflammaging” that accelerates virtually every aging hallmark. As the inflammatory burden rises with age, CD38 activity rises with it, consuming NAD+ faster than biosynthesis can compensate.
2. Reduced Nampt expression. Nampt (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the salvage pathway — the main route by which mammalian cells recycle nicotinamide back into NAD+. Its expression falls with age, reducing recycling efficiency.
3. Increased PARP demand. Accumulated DNA damage in aged cells drives higher PARP activity for repair. PARP consumes NAD+ stoichiometrically, further depleting the pool.

The downstream consequences are well-characterised: mitochondrial dysfunction, reduced metabolic flexibility, impaired circadian oscillation, attenuated stress responses, and slowed tissue repair. In clinical practice, these show up as fatigue that doesn’t resolve with sleep, prolonged recovery from illness or exercise, cognitive slowing, and increasingly poor glucose tolerance.

The NAD+ Precursor Landscape

Nicotinamide Mononucleotide (NMN)

NMN sits one enzymatic step away from NAD+ in the biosynthesis pathway: NMN → NAD+ via the enzyme NMNAT. For a time, its absorption was debated — whether oral NMN could even cross the intestinal epithelium intact before being degraded to NR or nicotinamide. A 2023 pharmacokinetic study by Irie et al. resolved much of this by demonstrating that a dedicated intestinal transporter (Slc12a8) shuttles NMN directly into enterocytes in mice, and human studies now show measurable blood NMN elevation within 30–60 minutes of dosing.

Clinically, NMN raises whole-blood NAD+ more rapidly and to higher peak concentrations than equivalent molar doses of NR in most head-to-head trials. A 12-week RCT in healthy older adults (Yoshino et al., Science 2021) showed 250 mg/day NMN improved insulin signalling in skeletal muscle independent of weight change — a finding with practical implications for metabolic ageing.

Practical dosing: 250 mg/day is the entry point; 500 mg/day is a common clinical target. Timing matters less than consistency, though morning dosing is often preferred to align with circadian NAD+ oscillation and avoid the mild activating effect some patients notice in the evening.

Form matters: Sublingual and liposomal NMN formats may further improve absorption, though direct comparative data are limited. The key variable in supplement quality is purity — third-party certificates of analysis for NMN ≥98% purity and absence of nicotinamide contamination should be standard.

Nicotinamide Riboside (NR)

NR is converted to NMN by the enzyme NRK1/2 before proceeding to NAD+, adding one enzymatic step compared with NMN. It has a longer clinical safety record than NMN — Phase I/II trials in humans date back to 2016 — and its gut tolerability profile is generally excellent.

In terms of blood NAD+ elevation, NR typically achieves 30–50% increases at doses of 500–1,000 mg/day. Multiple trials including the NIAGEN studies have confirmed this reproducibly across ages. A notable limitation is that a proportion of orally delivered NR is de-phosphorylated to nicotinamide in the gut lumen and liver before reaching systemic circulation; this nicotinamide is then recycled via Nampt but is not equivalent to direct NAD+ precursor delivery.

For most patients starting a longevity supplement protocol, NR represents a reasonable, well-tolerated entry point with a strong safety dataset. For those who are more depleted, have post-viral fatigue, or are optimising aggressively, upgrading to NMN or IV NAD+ is clinically justified.

NADH (Reduced Nicotinamide Adenine Dinucleotide)

NADH is the reduced form of NAD+ — it carries electrons within the mitochondrial electron transport chain. Oral NADH has poor and variable bioavailability: the molecule is unstable in the gut environment, and gastric acid degrades a substantial fraction before absorption. Enteric-coated formulations mitigate this somewhat.

Despite these limitations, NADH has the strongest randomised evidence base in a specific clinical niche: chronic fatigue syndrome and fibromyalgia. A 2015 RCT by Castro-Marrero et al. demonstrated that combined NADH (20 mg) and CoQ10 (200 mg) significantly reduced fatigue and improved cognitive function versus placebo in CFS patients over 8 weeks. The mechanism may relate partly to mitochondrial electron carrier replenishment and partly to antioxidant effects via the NADH/NAD+ redox ratio.

In my practice, NADH is most useful as an adjunct in patients with severe, persistent fatigue who have already maximised NMN/NR dosing — not as a first-line NAD+ booster.

NAD3 and Emerging Blends

NAD3 is a trademarked compound combining nicotinamide with a theacrine-pterostilbene complex designed to synergistically activate SIRT1 and SIRT3. Human pharmacokinetic data are limited, but a 2021 pilot study showed increases in whole-blood NAD+ at 8 weeks. Some commercial formulations combine NMN with pterostilbene or resveratrol for sirtuin co-activation. These stacks are conceptually sound but the incremental benefit over high-quality NMN alone has not been established in large trials.

Oral vs. IV NAD+: What the Evidence Says

Intravenous NAD+ infusion bypasses the entire gastrointestinal and hepatic first-pass barrier, delivering NAD+ directly to systemic circulation at 100% bioavailability. The clinical applications where IV NAD+ outperforms oral supplementation are not subtle:

• Acute deficiency states (post-viral syndrome, post-operative fatigue, addiction recovery)
• Neurological symptoms (brain fog, cognitive impairment with objective testing abnormalities)
• Post-chronic-Lyme and POTS — where mitochondrial dysfunction is profound and gut motility may compromise absorption

IV NAD+ at doses of 500–1,000 mg typically produces measurable clinical improvement within 2–5 sessions. Oral supplementation, by contrast, takes 4–12 weeks of consistent dosing to meaningfully shift whole-blood NAD+ levels. The two modalities are not mutually exclusive: our standard protocol uses an IV loading phase followed by oral NMN maintenance, with quarterly IV boosters for patients in longevity programs.

One important nuance: IV NAD+ causes a dose-dependent flushing and tightness reaction that is not a side effect of oral precursors. Slow infusion rates (< 7 mg/minute) and appropriate monitoring resolve this in virtually all cases.

Dosing, Timing, and Cofactors

TMG (Trimethylglycine) — The Essential Co-pilot

This is the most overlooked component of any NAD+ supplementation protocol. When NMN and NR are converted to NAD+, one downstream pathway produces nicotinamide, which must be methylated and excreted by the liver. This methylation consumes S-adenosylmethionine (SAM), a universal methyl donor. In patients supplementing with high-dose NMN, chronic SAM depletion can manifest as elevated homocysteine, mood flattening, or fatigue — counterproductive outcomes.

TMG (500–1,000 mg/day) donates methyl groups directly, regenerating SAM and keeping homocysteine in the normal range. At this point I consider TMG non-negotiable alongside NAD+ precursor dosing of 500 mg/day or more. For patients with confirmed MTHFR polymorphisms, methylated B-vitamins (methylfolate, methylcobalamin) add further protection.

Resveratrol and Sirtuin Activation

NAD+ is the required cofactor for sirtuin enzymes (SIRT1–7). Sirtuins govern a broad transcriptional programme including mitochondrial biogenesis (via PGC-1α), autophagy induction, and DNA damage response. Resveratrol activates SIRT1 allosterically — but only in the presence of adequate NAD+. This is the rationale for the popular NMN + resveratrol combination stack (as popularised by David Sinclair’s research group at Harvard).

The clinical evidence for adding resveratrol specifically is more modest than for NMN/NR alone, but the mechanistic logic is strong enough that I incorporate 250–500 mg trans-resveratrol in patients pursuing aggressive longevity protocols. Timing with a fat-containing meal substantially improves resveratrol absorption.

Pterostilbene vs. Resveratrol

Pterostilbene is a methylated analogue of resveratrol with approximately 80% oral bioavailability versus 30–40% for resveratrol, and a longer half-life. In doses of 50–150 mg/day it achieves comparable SIRT1 activation with a better pharmacokinetic profile. For patients who want a single sirtuin activator, pterostilbene is my preferred choice.

Who Benefits Most: Clinical Scenarios

The high-performing 40–55 year old who is metabolically healthy but noticing slower recovery: 250–500 mg NMN + 500 mg TMG + 250 mg pterostilbene, morning fasted. Expect perceptible energy improvement at 4–6 weeks; reassess whole-blood NAD+ at 12 weeks.

Post-viral fatigue (long COVID, EBV reactivation): The mitochondrial hit in post-viral syndromes is substantial and often includes CD38-driven NAD+ depletion from sustained immune activation. IV NAD+ loading (4–6 sessions) followed by 500 mg NMN + NADH 10 mg + CoQ10 200 mg oral maintenance is the protocol I use most in this population.

Chronic Lyme and co-infection fatigue: Biofilm-driven chronic infection sustains the same CD38/inflammation loop as post-viral states. NMN oral supports mitochondrial function between IV treatments but rarely corrects the energy deficit on its own until the infectious burden is addressed.

Older adults (65+) with cognitive concerns: NR has the most reassuring safety data in older adults; NMN is also appropriate. Emphasise the TMG co-supplementation point — homocysteine elevation in this age group carries cardiovascular and cognitive risk that should not be worsened by NAD+ protocol-induced methylation burden.

Active addiction recovery: IV NAD+ here is unambiguous — oral supplementation cannot achieve the rapid CNS NAD+ repletion that supports the neurological recovery phase. Several published protocols use 1,000 mg IV NAD+ over 8–10 hours daily for 10 days.

Safety Profile and What to Watch For

Oral NMN and NR have been tested in multiple RCTs up to 24 weeks with excellent tolerability. No hepatotoxicity, nephrotoxicity, or serious adverse events have been reported at doses up to 1,200 mg/day. The most common minor complaint is mild GI upset at higher doses, which resolves with food co-administration.

Theoretical concerns to monitor:

• Homocysteine elevation: Prevented by TMG co-supplementation. Monitor at baseline and 3 months.
• PARP inhibition competition: Some preclinical data suggest that very high NAD+ could theoretically blunt PARP signalling. This remains unproven in humans and is not a practical concern at clinical doses.
• Cancer promotion: The theoretical concern that NAD+ could fuel rapidly dividing cancer cells is frequently raised. The current evidence does not support withholding NAD+ precursors from cancer patients, but active malignancy is a context where I discuss the theoretical issue with patients and defer to oncology guidance.

Related Articles

• NAD IV Therapy: What to Expect From Infusion Treatments — clinical protocol for intravenous NAD+ and how it compares to oral precursors in real-world outcomes.
• NMN vs NR vs NAD+: A Physician’s Comparison — detailed pharmacokinetic comparison of the two leading oral precursor molecules.
• NAD Injections vs Oral Supplements — subcutaneous NAD+ injections as a middle-ground option between oral and IV routes.
• NAD IV Side Effects: What the Flushing and Tightness Really Mean — managing the most common reactions to NAD+ infusions.
• Anti-Aging Supplements: A Physician’s Personal Stack — where NAD+ precursors fit within a comprehensive longevity supplement strategy.

References

1. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PMID: 34099519
2. Irie J, Inagaki E, Fujita M, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020;67(2):153–160. PMID: 31685720
3. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMID: 27721479
4. Castro-Marrero J, Sáez-Francàs N, Segundo MJ, et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome: A randomized, controlled, double-blind trial. Clin Nutr. 2016;35(4):826–834. PMID: 26115440
5. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside — the current state of research and therapeutic uses. Nutrients. 2020;12(6):1616. PMID: 32486076
6. Gomes AP, Price NL, Ling AJY, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. PMID: 24360282
7. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139. PMID: 27304511